Gain Therapeutics Statistics
Total Valuation
GANX has a market cap or net worth of $51.43 million. The enterprise value is $40.41 million.
Important Dates
The last earnings date was Tuesday, November 10, 2026, before market open.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GANX has 44.53 million shares outstanding. The number of shares has increased by 36.92% in one year.
| Current Share Class | 44.53M |
| Shares Outstanding | 44.53M |
| Shares Change (YoY) | +36.92% |
| Shares Change (QoQ) | +2.08% |
| Owned by Insiders (%) | 2.27% |
| Owned by Institutions (%) | 19.58% |
| Float | 42.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.15 |
| P/TBV Ratio | 5.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.36, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.36 |
| Quick Ratio | 5.07 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -223.94% and return on invested capital (ROIC) is -127.64%.
| Return on Equity (ROE) | -223.94% |
| Return on Assets (ROA) | -91.45% |
| Return on Invested Capital (ROIC) | -127.64% |
| Return on Capital Employed (ROCE) | -163.01% |
| Weighted Average Cost of Capital (WACC) | 5.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$856,300 |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GANX has paid $429,741 in taxes.
| Income Tax | 429,741 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.16% in the last 52 weeks. The beta is 0.30, so GANX's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | -58.16% |
| 50-Day Moving Average | 1.43 |
| 200-Day Moving Average | 1.81 |
| Relative Strength Index (RSI) | 48.27 |
| Average Volume (20 Days) | 734,978 |
Short Selling Information
The latest short interest is 3.89 million, so 8.74% of the outstanding shares have been sold short.
| Short Interest | 3.89M |
| Short Previous Month | 3.19M |
| Short % of Shares Out | 8.74% |
| Short % of Float | 9.13% |
| Short Ratio (days to cover) | 6.39 |
Income Statement
| Revenue | n/a |
| Gross Profit | -8.57M |
| Operating Income | -17.71M |
| Pretax Income | -17.55M |
| Net Income | -17.98M |
| EBITDA | -17.66M |
| EBIT | -17.71M |
| Earnings Per Share (EPS) | -$0.43 |
Full Income Statement Balance Sheet
The company has $11.70 million in cash and $676,706 in debt, with a net cash position of $11.02 million or $0.25 per share.
| Cash & Cash Equivalents | 11.70M |
| Total Debt | 676,706 |
| Net Cash | 11.02M |
| Net Cash Per Share | $0.25 |
| Equity (Book Value) | 10.15M |
| Book Value Per Share | 0.23 |
| Working Capital | 10.33M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -17.07M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 46,965 |
| Net Borrowing | -100,464 |
| Free Cash Flow | -17.07M |
| FCF Per Share | -$0.38 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -36.92% |
| Shareholder Yield | -36.92% |
| Earnings Yield | -37.35% |
| FCF Yield | -32.77% |
Analyst Forecast
The average price target for GANX is $6.60, which is 471.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.60 |
| Price Target Difference | 471.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |